NotesFAQContact Us
Collection
Advanced
Search Tips
Showing 1 to 15 of 16 results Save | Export
Economic Evaluation of Anti-Epileptic Medicines for Autistic Children with Epilepsy
Peer reviewed Peer reviewed
Direct linkDirect link
Michela Tinelli M; Aine Roddy; Martin Knapp; Celso Arango; Maria Andreina Mendez; James Cusack; Declan Murphy; Roberto Canitano; Bethany Oakley; Vinciane Quoidbach – Journal of Autism and Developmental Disorders, 2024
We examine the cost-effectiveness of treating epilepsy with anti-epileptic medicines in autistic children, looking at impacts on healthcare providers (in England, Ireland, Italy and Spain) and children's families (in Ireland). We find carbamazepine to be the most cost-effective drug to try first in children with newly diagnosed focal seizures. For…
Descriptors: Foreign Countries, Autism Spectrum Disorders, Epilepsy, Pharmacology
Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder
Peer reviewed Peer reviewed
Direct linkDirect link
Henneberry, Erin; Lamy, Martine; Dominick, Kelli C.; Erickson, Craig A. – Journal of Autism and Developmental Disorders, 2021
Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of…
Descriptors: Autism, Pervasive Developmental Disorders, Drug Therapy, Pharmacology
Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials)
Peer reviewed Peer reviewed
Direct linkDirect link
Crutel, Véronique; Lambert, Estelle; Penelaud, Pierre-François; Albarrán Severo, Cristina; Fuentes, Joaquin; Rosier, Antoine; Hervás, Amaia; Marret, Stéphane; Oliveira, Guiomar; Parellada, Mara; Kyaga, Simon; Gouttefangeas, Sylvie; Bertrand, Marianne; Ravel, Denis; Falissard, Bruno – Journal of Autism and Developmental Disorders, 2021
There are currently no approved pharmacological treatments to improve social reciprocity and limit repetitive and rigid behaviors in autism spectrum disorder (ASD). We describe the design of two Phase III studies evaluating the efficacy/safety of bumetanide oral liquid formulation in ASD. These are international, multicenter, randomized,…
Descriptors: Autism, Pervasive Developmental Disorders, Children, Adolescents
Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice
Peer reviewed Peer reviewed
Direct linkDirect link
Siegel, Matthew; Beaulieu, Amy A. – Journal of Autism and Developmental Disorders, 2012
This paper presents a systematic review, rating and synthesis of the empirical evidence for the use of psychotropic medications in children with autism spectrum disorders (ASD). Thirty-three randomized controlled trials (RCTs) published in peer-reviewed journals qualified for inclusion and were coded and analyzed using a systematic evaluative…
Descriptors: Evidence, Autism, Pharmacology, Drug Therapy
Brief Report: Social Disability in Autism Spectrum Disorder--Results from Research Units on Pediatric Psychopharmacology (RUPP) Autism Network Trials
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; Hallett, Victoria; Aman, Michael G.; McDougle, Christopher J.; Arnold, L. Eugene; McCracken, James T.; Tierney, Elaine; Deng, Yanhong; Dziura, James; Vitiello, Benedetto – Journal of Autism and Developmental Disorders, 2013
There is growing interest in measuring social disability as a core element of autism spectrum disorders in medication trials. We conducted a secondary analysis on the Aberrant Behavior Checklist Social Withdrawal subscale using data from two federally-funded, multi-site, randomized trials with risperidone. Study 1 included 52 subjects assigned to…
Descriptors: Autism, Pharmacology, Effect Size, Pervasive Developmental Disorders
Design and Subject Characteristics in the Federally-Funded Citalopram Trial in Children with Pervasive Developmental Disorders
Peer reviewed Peer reviewed
Direct linkDirect link
Scahill, Lawrence; McCracken, James T.; Bearss, Karen; Robinson, Fay; Hollander, Eric; King, Bryan; Bregman, Joel; Sikich, Lin; Dukes, Kimberly; Sullivan, Lisa; Anagnostou, Evdokia; Donnelly, Craig; Kim, Young-Shin; Ritz, Louise; Hirtz, Deborah; Wagner, Ann – Journal of Autism and Developmental Disorders, 2012
The Studies to Advance Autism Research and Treatment Network conducted a randomized trial with citalopram in children with Pervasive developmental disorders (PDDs). We present the rationale, design and sample characteristics of the citalopram trial. Subjects (128 boys, 21 girls) had a mean age of 9.3 (plus or minus 3.12) years; 132 (88.6%) were…
Descriptors: Pharmacology, Drug Therapy, Pervasive Developmental Disorders, Autism
The Heavy Burden of Psychiatric Comorbidity in Youth with Autism Spectrum Disorders: A Large Comparative Study of a Psychiatrically Referred Population
Peer reviewed Peer reviewed
Direct linkDirect link
Joshi, Gagan; Petty, Carter; Wozniak, Janet; Henin, Aude; Fried, Ronna; Galdo, Maribel; Kotarski, Meghan; Walls, Sarah; Biederman, Joseph – Journal of Autism and Developmental Disorders, 2010
The objective of the study was to systematically examine patterns of psychiatric comorbidity in referred youth with autism spectrum disorders (ASD) including autistic disorder and pervasive developmental disorder not otherwise specified. Consecutively referred children and adolescents to a pediatric psychopharmacology program were assessed with…
Descriptors: Autism, Pharmacology, Pervasive Developmental Disorders, Comparative Analysis
Open-Label Memantine in Fragile X Syndrome
Peer reviewed Peer reviewed
Direct linkDirect link
Erickson, Craig A.; Mullett, Jennifer E.; McDougle, Christopher J. – Journal of Autism and Developmental Disorders, 2009
Glutamatergic dysfunction is implicated in the pathophysiology of fragile X syndrome (FXS). The purpose of this pilot study was to examine the effectiveness and tolerability of memantine for a number of target symptoms associated with FXS. Medical records describing open-label treatment with memantine in 6 patients with FXS and a comorbid…
Descriptors: Mental Retardation, Rating Scales, Patients, Genetic Disorders
[[superscript 3]H]-Flunitrazepam-Labeled Benzodiazepine Binding Sites in the Hippocampal Formation in Autism: A Multiple Concentration Autoradiographic Study
Peer reviewed Peer reviewed
Direct linkDirect link
Guptill, Jeffrey T.; Booker, Anne B.; Gibbs, Terrell T.; Kemper, Thomas L.; Bauman, Margaret L.; Blatt, Gene J. – Journal of Autism and Developmental Disorders, 2007
Increasing evidence indicates that the GABAergic system in cerebellar and limbic structures is affected in autism. We extended our previous study that found reduced [[superscript 3]H] flunitrazepam-labeled benzodiazepine sites in the autistic hippocampus to determine whether this reduction was due to a decrease in binding site number (B [subscript…
Descriptors: Autism, Brain, Drug Therapy, Comparative Analysis
Assessment in Multisite Randomized Clinical Trials of Patients with Autistic Disorder: The Autism RUPP Network.
Peer reviewed Peer reviewed
Arnold, L. Eugene; Aman, Michael G.; Martin, Andres; Collier-Crespin, Angie; Vitiello, Benedetto; Tierney, Elaine; Asarnow, Robert; Bell-Bradshaw, Felicia; Freeman, Betty Jo; Gates-Ulanet, Patricia; Klin, Ami; McCracken, James T.; McDougle, Christopher J.; McGough, James J.; Posey, David J.; Scahill, Lawrence; Swiezy, Naomi B.; Ritz, Louise; Volkmar, Fred – Journal of Autism and Developmental Disorders, 2000
This paper explains how the Autism Research Units on Pediatric Psychopharmacology (RUPP Autism Network) resolved common assessment problems including communication problems compromising use of the patient as informant, broad subject heterogeneity, difficulties in assessing low-end IQs, scarcity of autism-adapted cognitive and neuropsychological…
Descriptors: Autism, Clinical Diagnosis, Evaluation Methods, Pediatrics
Brief Report: Psychopharmacology of Autism Spectrum Disorders.
Peer reviewed Peer reviewed
Lewis, Mark H. – Journal of Autism and Developmental Disorders, 1996
This paper reviews recent findings on the efficacy of psychopharmacological interventions in autism, points out gaps in knowledge of the effects of specific drug classes, and suggests research directions for the future. (Author/DB)
Descriptors: Autism, Drug Therapy, Intervention, Outcomes of Treatment
Growth Hormone Response to L-Dopa and Clonidine in Autistic Children.
Peer reviewed Peer reviewed
Realmuto, George M.; And Others – Journal of Autism and Developmental Disorders, 1990
Seven medication-free autistic subjects (ages 6-19) were administered clonidine and L-Dopa to investigate neuroendocrine responses through changes in growth hormone levels. Findings showed that, compared to normal controls, the L-Dopa-stimulated growth hormone peak was delayed and the clonidine growth hormone peak was premature. (Author/JDD)
Descriptors: Adolescents, Autism, Children, Drug Therapy
Brief Report: Response to Methylphenidate in Two Children with William Syndrome.
Peer reviewed Peer reviewed
Power, Thomas J.; And Others – Journal of Autism and Developmental Disorders, 1997
This study explored the use of methylphenidate with two boys (ages 7 and 8 years) with Williams syndrome, a genetic disorder frequently accompanied by symptoms associated with Attention Deficit Hyperactivity Disorder (ADHD). Both boys performed optimally on 10 mg of methylphenidate administered twice daily, although one displayed increased…
Descriptors: Attention Deficit Disorders, Behavior Problems, Children, Drug Therapy
A Crossover Study of Risperidone in Children, Adolescents and Adults with Mental Retardation
Peer reviewed Peer reviewed
Direct linkDirect link
Hellings, Jessica A.; Zarcone, Jennifer R.; Reese, R. Matthew; Valdovinos, Maria G.; Marquis, Janet G.; Fleming, Kandace K.; Schroeder, Stephen R. – Journal of Autism and Developmental Disorders, 2006
Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies. This longer-duration study includes a broad sample. Forty subjects, aged 8-56 years (mean=22), all with mental retardation and 36 with autism spectrum disorders participated in this 22-week crossover study, with 24 weeks of open maintenance…
Descriptors: Drug Therapy, Mental Retardation, Pervasive Developmental Disorders, Children
Behavioral Effects of Org 2766, a Synthetic Analog of the Adrenocorticotrophic Hormone (4-9), in 14 Outpatient Autistic Children.
Peer reviewed Peer reviewed
Buitelaar, Jan K.; And Others – Journal of Autism and Developmental Disorders, 1990
Fourteen autistic children (ages 5-13) were administered Org 2766 (a synthetic analog of the adrenocorticotrophic hormone 4-9) or a placebo for 4 weeks. The hormone appeared to decrease stereotypic behavior and increase such behaviors as "change toys,""locomote," and "talk," though Aberrant Behavior Checklist ratings…
Descriptors: Autism, Behavior Change, Behavior Problems, Behavior Rating Scales
Previous Page | Next Page »
Pages: 1  |  2